1 day ago
It's been a disappointing couple of years for shareholders of biotechnology outfit CRISPR Therapeutics (NASDAQ: CRSP). This stock's barely up since the end of 2022, lagging the broad market's gains. It's not the performance that investors keeping tabs on this company were expecting, given its potential.
Don't be discouraged, though. While still speculative like most young biotech names, CRISPR Therapeutics remains a compelling prospect for investors who can stomach the risk and its inevitable volatility. Here's why.
Missed AI's "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our **** ysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
On the off-chance you're reading this and aren't already familiar with the company, CRISPR Therapeutics is a drug developer that specializes in gene editing.
It's probably an area you've heard a great deal about. No gene-editing drugs were actually on the market in the United States until CRISPR Therapeutics' Casgevy was approved by the FDA as a treatment for sickle cell disease in late 2023. Any and all gene therapies currently on the market followed this pioneer's foray. Being first is a well-deserved accolade for the company, too, which was co-founded by Dr. Emmanuelle Charpentier, who was one of the co-discoverers of the CRISPR/Cas9 gene-editing mechanism that makes Casgevy work.
#crispr #gene #company
Don't be discouraged, though. While still speculative like most young biotech names, CRISPR Therapeutics remains a compelling prospect for investors who can stomach the risk and its inevitable volatility. Here's why.
Missed AI's "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our **** ysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
On the off-chance you're reading this and aren't already familiar with the company, CRISPR Therapeutics is a drug developer that specializes in gene editing.
It's probably an area you've heard a great deal about. No gene-editing drugs were actually on the market in the United States until CRISPR Therapeutics' Casgevy was approved by the FDA as a treatment for sickle cell disease in late 2023. Any and all gene therapies currently on the market followed this pioneer's foray. Being first is a well-deserved accolade for the company, too, which was co-founded by Dr. Emmanuelle Charpentier, who was one of the co-discoverers of the CRISPR/Cas9 gene-editing mechanism that makes Casgevy work.
#crispr #gene #company
2 months ago
Cathie Wood, CEO of Ark Invest, is known for her aggressive investment style. Ark Innovation ETF is heavily invested in growth stocks, including Tesla, Tempus AI, and CRISPR Therapeutics. Roughly half of the fund's ******* ets are invested in just 10 companies.
Among the fund's top holdings is ******* e Exploration Technologies (NASDAQ: SPCX). The ******* e stock accounts for around 4.5% of the fund's invested ******* ets.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Immediately after its IPO, ******* eX stock soared well above $200. After a sharp correction, however, shares now trade below their initial IPO price of $135 per share.
Wood capitalized on the correction by purchasing more ******* eX stock. According to reports, she purchased $21.3 million in ******* eX stock across multiple funds as the price fell.
#SpaceX #wood
Among the fund's top holdings is ******* e Exploration Technologies (NASDAQ: SPCX). The ******* e stock accounts for around 4.5% of the fund's invested ******* ets.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Immediately after its IPO, ******* eX stock soared well above $200. After a sharp correction, however, shares now trade below their initial IPO price of $135 per share.
Wood capitalized on the correction by purchasing more ******* eX stock. According to reports, she purchased $21.3 million in ******* eX stock across multiple funds as the price fell.
#SpaceX #wood
2 months ago
If you're keeping an eye on gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP), you probably already know the up-and-coming biopharmaceutical outfit is a favorite of Ark Investment Management's CEO and chief stock picker, Cathie Wood. As of the latest look, the company's holding nearly $270 million worth of this name in its flagship Ark Innovation ETF (NYSEMKT: ARKK) and another $92 million worth in the smaller Ark Genomic Revolution ETF (NYSEMKT: ARKG).
What is surprising is why Wood is holding it. Although patient-specific genomic repair remains a key part of this stock's bullish thesis, CRISPR Therapeutics' developmental work on another front has gone largely unnoticed and may not be reflected in the stock's price.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
CRISPR Therapeutics' founders essentially found a way of repairing damaged DNA with a corrected genetic sequence. It was the first company to ever win the FDA's approval for a gene-editing drug, in fact. That's Casgevy -- for the treatment of sickle cell disease -- which was approved in late 2023. Now the same patient-specific approach is being tested as a therapy for handful of other genetic diseases.
The underlying science, however, isn't limited to a customized therapy for each patient. Gene editing can be used to create off-the-shelf treatments for all patients with a particular disease.
#editing
What is surprising is why Wood is holding it. Although patient-specific genomic repair remains a key part of this stock's bullish thesis, CRISPR Therapeutics' developmental work on another front has gone largely unnoticed and may not be reflected in the stock's price.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
CRISPR Therapeutics' founders essentially found a way of repairing damaged DNA with a corrected genetic sequence. It was the first company to ever win the FDA's approval for a gene-editing drug, in fact. That's Casgevy -- for the treatment of sickle cell disease -- which was approved in late 2023. Now the same patient-specific approach is being tested as a therapy for handful of other genetic diseases.
The underlying science, however, isn't limited to a customized therapy for each patient. Gene editing can be used to create off-the-shelf treatments for all patients with a particular disease.
#editing
2 months ago
Genetic engineering and weight-loss innovation have become focal points for modern healthcare investors. Choosing between CRISPR Therapeutics AG (NASDAQ:CRSP) and Viking Therapeutics (NASDAQ:VKTX) depends on your appetite for risk and your belief in their distinct medical breakthroughs.
CRISPR Therapeutics uses gene-editing technology to address diseases at their genetic source, while Viking focuses on metabolic conditions such as obesity that affect millions globally. Both companies represent high-potential opportunities within the biotechnology ******* e, though they currently sit at very different stages of their respective commercial journeys.
CRISPR Therapeutics focuses on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform. The company recently achieved a major milestone with the commercial launch of Casgevy, a treatment for sickle cell disease and transfusion-dependent beta thalassemia. It operates under a strategic collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX), which manages global manufacturing and commercialization. Customer concentration like this adds a layer of risk to the business, as CRISPR Therapeutics relies on this partner for 60% of its profits and losses.
In FY 2025, revenue was about $3.5 million, representing a decrease of approximately 90% from the prior year. This decline is largely due to the transition from receiving one-time milestone payments to building out long-term commercial revenue streams from its approved products. The company reported a net loss of close to $581.6 million. Investing in biotech stocks requires an understanding of how these companies move from early research to global commercialization.
As of its December 2025 balance sheet, the debt-to-equity ratio was roughly 0.2x. This ratio measures total debt relative to the equity shareholders have in the company, with a lower number indicating less reliance on borrowed money. Free cash flow was negative $345.9 million, representing the amount of cash a company generates after paying for capital expenditures.
CRISPR Therapeutics uses gene-editing technology to address diseases at their genetic source, while Viking focuses on metabolic conditions such as obesity that affect millions globally. Both companies represent high-potential opportunities within the biotechnology ******* e, though they currently sit at very different stages of their respective commercial journeys.
CRISPR Therapeutics focuses on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform. The company recently achieved a major milestone with the commercial launch of Casgevy, a treatment for sickle cell disease and transfusion-dependent beta thalassemia. It operates under a strategic collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX), which manages global manufacturing and commercialization. Customer concentration like this adds a layer of risk to the business, as CRISPR Therapeutics relies on this partner for 60% of its profits and losses.
In FY 2025, revenue was about $3.5 million, representing a decrease of approximately 90% from the prior year. This decline is largely due to the transition from receiving one-time milestone payments to building out long-term commercial revenue streams from its approved products. The company reported a net loss of close to $581.6 million. Investing in biotech stocks requires an understanding of how these companies move from early research to global commercialization.
As of its December 2025 balance sheet, the debt-to-equity ratio was roughly 0.2x. This ratio measures total debt relative to the equity shareholders have in the company, with a lower number indicating less reliance on borrowed money. Free cash flow was negative $345.9 million, representing the amount of cash a company generates after paying for capital expenditures.
